MGMT promoter methylation status in clival chordoma

Gianluca Marucci, Luca Morandi, Diego Mazzatenta, Giorgio Frank, Ernesto Pasquini, Maria Pia Foschini

Research output: Contribution to journalArticlepeer-review


Chordomas are rare, slow-growing neoplasms, characterized by locally aggressive growth patterns and high local recurrence rates. To the best of our knowledge, the MGMT promoter methylation status has not been studied in a population of patients with chordomas to determine if a biologic rationale exists to support the use of temozolomide. We here show for the first time that methylation of MGMT promoter is present in a significant portion or recurring clival chordomas; on the contrary in clival chordomas without recurrence MGMT promoter was always unmethylated (p = 0.0317). Although these observations need to be confirmed in a larger study population, our results (1) indicate that methylation of MGMT promoter is present in a significant portion of recurring chordomas, and (2) prompt further investigation into the potential role of temozolomide as an adjuvant treatment of these tumors.

Original languageEnglish
Pages (from-to)271-276
Number of pages6
JournalJournal of Neuro-Oncology
Issue number2
Publication statusPublished - 2014


  • Chordoma
  • Clivus
  • Methylation
  • MGMT
  • Temozolomide

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology
  • Medicine(all)


Dive into the research topics of 'MGMT promoter methylation status in clival chordoma'. Together they form a unique fingerprint.

Cite this